In a patient with chronic lymphocytic leukemia and a white blood cell count of 374 × 10⁹/L presenting to the emergency department, what are the emergent differential diagnoses and what immediate management steps should be taken?

Emergency Management of CLL with WBC 374 × 10⁹/L

In a CLL patient presenting to the ED with WBC 374 × 10⁹/L, immediately assess for leukostasis (respiratory distress, altered mental status, hypoxia) and tumor lysis syndrome (hyperkalemia, hyperuricemia, hyperphosphatemia, renal failure), as these are life-threatening emergencies requiring urgent intervention before any definitive CLL treatment.

Immediate Life-Threatening Differential Diagnoses

1. Leukostasis Syndrome

While leukostasis is exceptional in CLL compared to acute leukemias 1, it can occur with extreme leukocytosis (>100 × 10⁹/L) 2. Your patient's WBC of 374 is well into the danger zone.

Clinical signs to assess immediately:

• Pulmonary: Tachypnea, hypoxia, respiratory distress
• Neurologic: Headache, confusion, slurred speech, somnolence, visual changes
• Cardiac: Signs of hyperviscosity

The diagnosis is clinical 2. If present, this is a medical emergency requiring prompt cytoreduction 3.

2. Tumor Lysis Syndrome (TLS)

Spontaneous TLS can occur as the initial presentation of CLL, even without prior cytotoxic therapy 4.

Check immediately:

• Potassium (>6.0 mmol/L with ECG changes = cardiac emergency)
• Uric acid (>8 mg/dL)
• Phosphate (>4.5 mg/dL)
• Calcium (hypocalcemia)
• Creatinine (acute kidney injury)
• LDH (markedly elevated)
• ECG (peaked T-waves, widened QRS)

3. Infectious Complications

With this degree of leukocytosis and CLL-associated immunodeficiency, assess for:

• Pneumonia (most common severe infection 5)
• Sepsis from encapsulated organisms (Streptococcus pneumoniae)
• Opportunistic infections if previously treated

Immediate ED Management Algorithm

Step 1: Stabilize Life-Threatening Complications (First 30 minutes)

If leukostasis present:

• Aggressive IV hydration (avoid overload if respiratory compromise)
• Hydroxyurea 50-100 mg/kg PO as immediate cytoreduction 2
• Avoid RBC transfusion (worsens hyperviscosity) unless Hb <7 g/dL 2
• Avoid platelet transfusion unless active bleeding
• Consider urgent leukapheresis (though controversial in CLL) 2, 1

If TLS present or high risk:

• Cardiac monitoring with continuous ECG if K+ >6.0
• Emergent potassium management: Calcium gluconate (if ECG changes), insulin/dextrose, albuterol, sodium bicarbonate
• Aggressive isotonic IV fluids (200-300 mL/hr if renal function permits) 4
• Allopurinol 300-600 mg PO immediately (or rasburicase 0.2 mg/kg IV if available and uric acid >8 mg/dL) 4
• Urgent nephrology consult for hemodialysis if: K+ >6.5 despite treatment, severe metabolic acidosis, oliguria/anuria, or progressive uremia 4

Step 2: Diagnostic Workup (Concurrent with stabilization)

Laboratory:

• CBC with differential, comprehensive metabolic panel
• Uric acid, phosphate, calcium, LDH
• Coagulation studies (PT/PTT, fibrinogen, D-dimer) to assess for DIC
• Blood cultures × 2 sets
• Inflammatory markers (CRP, procalcitonin)

Imaging:

• Chest X-ray or CT if any respiratory symptoms (pneumonia vs leukostasis) 5
• Consider CT head if neurologic symptoms

Microbiology if infection suspected:

• Urinary antigens for Legionella and Pneumococcus 5
• Nasopharyngeal swab for respiratory viruses including SARS-CoV-2 5
• Sputum culture if productive cough

Step 3: Urgent Hematology Consultation

Contact hematology/oncology immediately for:

• Confirmation of CLL diagnosis (if not previously established)
• Flow cytometry if diagnosis uncertain
• Assessment for treatment indication per ESMO criteria 6
• Initiation of cytoreductive therapy

Step 4: Cytoreduction Strategy

While awaiting hematology:

• Hydroxyurea is the safest immediate option 2
• Do NOT start definitive CLL therapy (BTKi, BCL2i, chemotherapy) in the ED without hematology input
• Genetic testing (del17p, TP53, IGHV) should be sent but does NOT delay emergency cytoreduction 6

Critical Pitfalls to Avoid

1. Do not transfuse RBCs in hyperleukocytosis unless Hb <7 g/dL—this worsens hyperviscosity and can precipitate leukostasis 2

2. Do not assume CLL is "chronic" and benign—extreme leukocytosis creates acute emergencies 4, 1

3. Do not delay hemodialysis if TLS with severe hyperkalemia or renal failure—this is immediately life-saving 4

4. Do not start definitive CLL treatment without genetic testing results and hematology input, but DO start hydroxyurea for cytoreduction 6, 2

5. Monitor for infection aggressively—CLL patients have profound immunodeficiency regardless of WBC count 5

Disposition

• Admit to ICU if leukostasis, severe TLS, or hemodynamic instability
• Admit to hematology service for all others with WBC >100 × 10⁹/L
• Serial monitoring of metabolic parameters every 4-6 hours during cytoreduction
• Continuous cardiac monitoring if any TLS present